Noxopharm is a clinical-stage drug development company focused on creating treatments for various types of solid tumor cancers and septic shock. The company's pipeline drug candidate, Veyonda, is currently being trialed to treat several types of cancer. Additionally, Noxopharm's R&D program is working on developing later generation drug candidates to meet unmet medical needs. The company has offices in Sydney and New York, making it a global player in the biotech industry.